SCHEMBL4307807

SCHEMBL4307807

CC(C)(C)OC(=O)N1CCC(N(Cc2cccc(C(F)(F)F)c2)c2ccc(F)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
GPR119 Q8TDV5 3/20 0.47
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
TGFBR1 P36897 1/20 0.46
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TACR1 P25103 3/20 0.45
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
PGR P06401 1/20 0.43
STS P08842 1/20 0.43
UBE2M P61081 1/20 0.43
DCUN1D1 Q96GG9 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306665 0.92 MEN1 (0.51) MEN1KMT2AGPR119TGFBR1TACR1
SCHEMBL4309355 0.89 MEN1 (0.57) MEN1KMT2AGPR119MAPTTGFBR1
SCHEMBL4310460 0.89 MEN1 (0.57) MEN1KMT2AGPR119MAPTTGFBR1
SCHEMBL4309350 0.89 MEN1 (0.67) MEN1KMT2AGPR119CYP2D6CYP2C9
SCHEMBL4311539 0.88 MEN1 (0.56) MEN1KMT2AGPR119POLBALDH1A1
SCHEMBL4312794 0.88 MEN1 (0.62) MEN1KMT2AGPR119JAK2JAK1
SCHEMBL4311495 0.87 DCUN1D1 (0.48) MEN1KMT2AALDH1A1TACR1PGR
SCHEMBL4306686 0.86 MEN1 (0.56) MEN1KMT2AGPR119TP53
SCHEMBL4304098 0.84 MEN1 (0.54) MEN1KMT2AGPR119CYP2D6CYP2C9
SCHEMBL4311345 0.84 KMT2A (0.58) MEN1KMT2AGPR119JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP claimed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US claimed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP claimed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO claimed
US-7488741-B2 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB PHARMA, S.A. (BE) 2009-02-10 US disclosed
EP-1693061-A1 Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases UCB, S.A. (BE) 2006-08-23 EP disclosed
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP disclosed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US disclosed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP disclosed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments PNMT, HTR5A, HTR4 MEN1 4456/4885KMT2A 1360/4885GPR119 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.